ursodeoxycholic acid (STN1013600) / Santen - LARVOL DELTA

OPSIS: Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (clinicaltrials.gov) - P2 | N=79 | Completed | Sponsor: Santen Inc. | Phase classification: P2a ➔ P2

Phase classification • Ophthalmology

OPSIS: Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (clinicaltrials.gov) - P2a | N=79 | Completed | Sponsor: Santen Inc. | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology

OPSIS: Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (clinicaltrials.gov) - P2a | N=79 | Active, not recruiting | Sponsor: Santen Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Ophthalmology

OPSIS: Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (clinicaltrials.gov) - P2a | N=75 | Recruiting | Sponsor: Santen Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology

OPSIS: Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (clinicaltrials.gov) - P2a | N=75 | Not yet recruiting | Sponsor: Santen Inc.

New P2a trial • Ophthalmology